These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29963233)

  • 1. ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer.
    Petrossian K; Kanaya N; Lo C; Hsu PY; Nguyen D; Yang L; Yang L; Warden C; Wu X; Pillai R; Bernal L; Huang CS; Kruper L; Yuan Y; Somlo G; Mortimer J; Chen S
    Oncotarget; 2018 Jun; 9(45):27736-27751. PubMed ID: 29963233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
    Gul A; Leyland-Jones B; Dey N; De P
    Am J Cancer Res; 2018; 8(12):2359-2376. PubMed ID: 30662797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress with palbociclib in breast cancer: latest evidence and clinical considerations.
    Rocca A; Schirone A; Maltoni R; Bravaccini S; Cecconetto L; Farolfi A; Bronte G; Andreis D
    Ther Adv Med Oncol; 2017 Feb; 9(2):83-105. PubMed ID: 28203301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
    Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
    Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Shah AN; Cristofanilli M
    Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
    Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ
    Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.
    Trapé AP; Liu S; Cortes AC; Ueno NT; Gonzalez-Angulo AM
    J Cancer; 2016; 7(8):947-56. PubMed ID: 27313785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
    Hopcroft L; Wigmore EM; Williamson SC; Ros S; Eberlein C; Moss JI; Urosevic J; Carnevalli LS; Talbot S; Bradshaw L; Blaker C; Gunda S; Owenson V; Hoffmann S; Sutton D; Jones S; Goodwin RJA; Willis BS; Rooney C; de Bruin EC; Barry ST
    NPJ Breast Cancer; 2023 Aug; 9(1):64. PubMed ID: 37543694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.
    Lange CA; Yee D
    Endocr Relat Cancer; 2011 Aug; 18(4):C19-24. PubMed ID: 21613412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
    Herrera-Abreu MT; Palafox M; Asghar U; Rivas MA; Cutts RJ; Garcia-Murillas I; Pearson A; Guzman M; Rodriguez O; Grueso J; Bellet M; Cortés J; Elliott R; Pancholi S; Baselga J; Dowsett M; Martin LA; Turner NC; Serra V
    Cancer Res; 2016 Apr; 76(8):2301-13. PubMed ID: 27020857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
    DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
    Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a CDK4/6 Inhibitor in a Patient with Breast Cancer and Liposarcoma: A Case Report and Review of the Literature.
    Loretan L; Moskovszky LE; Kurrer M; Exner GU; Trojan A
    Breast Care (Basel); 2019 Oct; 14(5):325-328. PubMed ID: 31798393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CDK4/6 in patients with cancer.
    Hamilton E; Infante JR
    Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.
    Thangavel C; Dean JL; Ertel A; Knudsen KE; Aldaz CM; Witkiewicz AK; Clarke R; Knudsen ES
    Endocr Relat Cancer; 2011 Jun; 18(3):333-45. PubMed ID: 21367843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK4/6 inhibition in breast cancer: current practice and future directions.
    Pernas S; Tolaney SM; Winer EP; Goel S
    Ther Adv Med Oncol; 2018; 10():1758835918786451. PubMed ID: 30038670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.
    Owsley J; Jimeno A; Diamond JR
    Drugs Today (Barc); 2016 Feb; 52(2):119-29. PubMed ID: 27092341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.